Charles Viviano, MD, PhD received his bachelor’s degree in Biology from Fairfield University and his doctorate in Toxicology from the University of North Carolina at Chapel Hill.  His research investigated the regulation of pulmonary surfactant phospholipids and apoproteins.  He continued that work as a postdoctoral associate in the Department of Pediatrics at Yale School of Medicine.  He attended medical school at the University of Connecticut where he also completed a surgical internship and a residency in Urology.  As a resident he conducted research in Peyronie’s Disease.  Following completion of his residency, he was in private practice in Connecticut for over 5 years before joining the faculty in the Division of Urology at Duke University School of Medicine for 4 years.  He focused on general urology and Men’s Health.  He joined the FDA as a Urology Medical Officer in the Division of Reproductive, Gastro-Renal, and Urological Devices (DRGUD) in ODE in 2015.  He is the Principal Investigator of an FDA-funded patient preference information research project entitled “Assessment of Patient Tolerance for Risk Associated with High Intensity Focused Ultrasound (HIFU) for the Ablation of Prostate Tissue in Men with Localized Prostate Cancer” and serves on the SPARED organizing committee.  Currently, he is the clinical deputy office director for OHT3 (Office of Gastrorenal, ObGyn, General Hospital and Urology Devices) in CDRH (Center for Devices and Radiological Health).